July 14, 2026
First Joint Clinical Assessments (JCAs): Key Lessons for EU HTA
Learn what the first EU Joint Clinical Assessments reveal about evidence planning, PICO strategy, and HTA readiness for successful market access.
Dedicated, sponsor-aligned medical writers embedded within your organization to provide scalable expertise across the development lifecycle.
When development portfolios expand, organizational structures shift, or internal teams reach capacity; medical writing can quickly become a bottleneck to regulatory progress.
ProPharma's FSP Medical Writing model provides dedicated, sponsor-aligned writers who integrate seamlessly into your organization, delivering continuity, scalability, and deep therapeutic expertise without increasing permanent headcount.
FSP models don't just add capacity, they create meaningful "organizational leverage". By shifting the operational management to the FSP partner, organizations significantly reduce administrative burden and unlock strategic capacity. Internal teams are no longer absorbed by managing the day-to-day execution and can instead focus on high-impact priorities such as advancing scientific strategy, shaping regulatory positions, and driving portfolio-level decisions.
Rather than outsourcing individual documents, this model delivers long-term capability: a stable team that operates within your processes, systems, and governance framework.
For project‑based deliverables, explore our Global Medical Writing & Transparency services.
Many sponsors adopt an FSP model during periods of transition, growth, or sustained volume pressure. Common drivers include:
Dedicated FSP writers function as an extension of your internal medical writing organization. We use your SOPs, templates, quality expectations, systems, and governance structure, participating in established communication and review processes. This embedded approach reduces onboarding time, preserves institutional knowledge, and enables consistent output across programs.
FSP Medical Writing teams can support document development across all stages of the drug development lifecycle:
Publishing in peer-reviewed journals is essential for scientific credibility, regulatory engagement, and clinical adoption. FSP teams provide dedicated support across the publication lifecycle: Manuscripts and abstracts
ProPharma supports biotech, pharmaceutical, and medical device/diagnostics organizations navigating diverse regulatory pathways and evidence requirements. Teams are matched to program complexity, therapeutic area, and modality to ensure relevant expertise and regulatory alignment.
This model is particularly effective when organizations require ongoing support across multiple programs, predictable demand over extended timelines, integration with internal teams, or scalability without hiring delays.
Shifting operational responsibilities can help reduce administrative and operational burden, allowing internal teams to reclaim time and focus. The result is a more agile, strategically aligned writing function that supports faster, more confident organizational progress.
Our FSP Medical Writing solutions provide the stability, expertise, and flexibility needed to sustain development momentum, even as priorities evolve. Contact our team to discuss how an embedded medical writing model can support your organization’s goals.
July 14, 2026
Learn what the first EU Joint Clinical Assessments reveal about evidence planning, PICO strategy, and HTA readiness for successful market access.
July 13, 2026
Explore how organizations can navigate regulatory complexity in clinical trials to achieve predictable study start-up timelines and operational excellence.
July 8, 2026
ProPharma unveils an AI-assisted capability to enhance ANDA submission development, improving efficiency and maintaining regulatory excellence for clients.
June 18, 2026
ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.
January 31, 2025
ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.
October 9, 2024
ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.
July 15, 2026
Product shortages involving essential medicines can create significant clinical and regulatory challenges, particularly when vulnerable patient populations depend on uninterrupted access to...
June 17, 2026
Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...
June 4, 2026
Artificial intelligence (AI) is a hot topic in Medical Information (MI), yet real-world evidence of its impact in regulated, human-led MI environments remains limited. Hear practical, evidence-based...
June 2, 2026
A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...
July 15, 2026
Product shortages involving essential medicines can create significant clinical and regulatory challenges, particularly when vulnerable patient populations depend on uninterrupted access to...
June 17, 2026
Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...